Current Editions
Seeking ‘continuous’ run of deals, BioMarin adds Fabry, Pompe drugs via $4.8B Amicus takeout
Dealmaker James Sabry says the California company has the financial might to enter a sequence of deals to augment its portfolio and pipeline
Deals
Product Development
A non-profit brought an abandoned rare disease gene therapy to market. Can the model scale?
Fondazione Telethon partners Wiskott-Aldrich with U.S. non-profit to facilitate market access
Brinsupri setback slices Insmed market cap — Clinical Report
Plus: Updates from Lilly in obesity, Takeda in psoriasis, and Moderna-CEPI
Finance
Raising the sun: Japan biotech looks to level up
Can a country rich in Nobel winners and blockbuster drugs grow its biotech culture?
Management Tracks
Cai succeeding Zhang as head of CSPC
Plus: AI leaders hired by ProFound, Nona and updates from PureTech, BeOne, Breyer Capital, NanOlogy LLC
BioCentury ISSN 1097-7201